The aforementioned studies confirmed that the VEGF receptor and mTOR are important targets for the treatment of RCC, and many targeted drugs have also been developed and applied in the clinical setting, improving the OS and progression-free survival of patients. Here, MTOR is linked to renal cell carcinoma.